Overview

At a Glance

 
  • Growing fundamental PCT business, a leading cell therapy development and manufacturing partner (CDMO)
    • Strategic global collaboration with Hitachi
    • Growing revenues (avg. 24%/year growth since 2013)
    • Projected >30% revenue growth in 2016 to >$30 million
    • Extensive list of noteworthy client companies
  • Promising T regulatory cell therapy (CLBS03) in Phase 2 for adolescents with recent-onset type 1 diabetes (T1D)
    • First FDA Fast Track designation granted for T1D; FDA Orphan designation; EU ATMP classification
    • Targeting partnerships post-proof of concept capitalizes on value inflection and provides potential PCT client stream

Stock Chart

Maximum 30 minute delay for quote.

Sign up to our e-mail list to receive Caladrius announcements.


Investor Relations Contact


Lippert/Heilshorn & Associates
Anne Marie Fields
Phone: +1-212-838-3777
E-mail: afields@lhai.com

Media Contact


Caladrius Biosciences, Inc.
Eric Powers
Director of Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@caladrius.com